{"title":"在转移性前列腺癌治疗中使用 177Lu 前列腺特异性膜抗原剂量测定法确定临界器官剂量。","authors":"Gulcihan Yilidir, Mustafa Demir","doi":"10.4103/jmp.jmp_12_24","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>This study aimed to perform dosimetry in patients with metastatic prostate cancer treated with <sup>177</sup>Lutetium (Lu) prostate-specific membrane antigen (PSMA)-617 radiopharmaceutical, calculating organ blood clearance and consequently determining the maximum tolerable treatment activity.</p><p><strong>Materials and methods: </strong>Eighteen patients with metastatic prostate cancer were enrolled in the study. Patients were administered 5.55 gigabecquerel (GBq) of <sup>177</sup>Lu-PSMA-617 radiopharmaceutical per treatment cycle through infusion. Blood samples (2 mL each) were collected at 2, 4, 6, 8, 18, 24, 36, and 44 h postinjection to assess the bone marrow absorbed dose. Organ doses were calculated using the OLINDA/EXM software based on scintigraphic images of the 18 patients who received <sup>177</sup>Lu-PSMA-617.</p><p><strong>Results: </strong>The blood clearance of <sup>177</sup>Lu-PSMA-617 radiopharmaceutical was determined to be bi-exponential. The mean absorbed doses for the parotid glands, kidneys, bone marrow, and liver were found to be 1.18 ± 0.27, 1.05 ± 0.3, 0.07 ± 0.05, and 0.31 ± 0.2 Gy/GBq, respectively. The radiation dose to the bone marrow was significantly lower than that to the kidneys and parotid glands. No dose limitations were necessary for kidneys and bone marrow in any of the patients.</p><p><strong>Conclusions: </strong>Our dosimetry results indicate that <sup>177</sup>Lu-PSMA-617 therapy is safe in terms of radiation toxicity.</p>","PeriodicalId":51719,"journal":{"name":"Journal of Medical Physics","volume":"49 2","pages":"304-310"},"PeriodicalIF":0.7000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11309138/pdf/","citationCount":"0","resultStr":"{\"title\":\"Determination of Critical Organ Doses with <sup>177</sup>Lu Prostate-specific Membrane Antigen Dosimetry in Metastatic Prostate Cancer Treatment.\",\"authors\":\"Gulcihan Yilidir, Mustafa Demir\",\"doi\":\"10.4103/jmp.jmp_12_24\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>This study aimed to perform dosimetry in patients with metastatic prostate cancer treated with <sup>177</sup>Lutetium (Lu) prostate-specific membrane antigen (PSMA)-617 radiopharmaceutical, calculating organ blood clearance and consequently determining the maximum tolerable treatment activity.</p><p><strong>Materials and methods: </strong>Eighteen patients with metastatic prostate cancer were enrolled in the study. Patients were administered 5.55 gigabecquerel (GBq) of <sup>177</sup>Lu-PSMA-617 radiopharmaceutical per treatment cycle through infusion. Blood samples (2 mL each) were collected at 2, 4, 6, 8, 18, 24, 36, and 44 h postinjection to assess the bone marrow absorbed dose. Organ doses were calculated using the OLINDA/EXM software based on scintigraphic images of the 18 patients who received <sup>177</sup>Lu-PSMA-617.</p><p><strong>Results: </strong>The blood clearance of <sup>177</sup>Lu-PSMA-617 radiopharmaceutical was determined to be bi-exponential. The mean absorbed doses for the parotid glands, kidneys, bone marrow, and liver were found to be 1.18 ± 0.27, 1.05 ± 0.3, 0.07 ± 0.05, and 0.31 ± 0.2 Gy/GBq, respectively. The radiation dose to the bone marrow was significantly lower than that to the kidneys and parotid glands. No dose limitations were necessary for kidneys and bone marrow in any of the patients.</p><p><strong>Conclusions: </strong>Our dosimetry results indicate that <sup>177</sup>Lu-PSMA-617 therapy is safe in terms of radiation toxicity.</p>\",\"PeriodicalId\":51719,\"journal\":{\"name\":\"Journal of Medical Physics\",\"volume\":\"49 2\",\"pages\":\"304-310\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2024-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11309138/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Medical Physics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/jmp.jmp_12_24\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/6/25 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Physics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jmp.jmp_12_24","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/25 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
Determination of Critical Organ Doses with 177Lu Prostate-specific Membrane Antigen Dosimetry in Metastatic Prostate Cancer Treatment.
Aim: This study aimed to perform dosimetry in patients with metastatic prostate cancer treated with 177Lutetium (Lu) prostate-specific membrane antigen (PSMA)-617 radiopharmaceutical, calculating organ blood clearance and consequently determining the maximum tolerable treatment activity.
Materials and methods: Eighteen patients with metastatic prostate cancer were enrolled in the study. Patients were administered 5.55 gigabecquerel (GBq) of 177Lu-PSMA-617 radiopharmaceutical per treatment cycle through infusion. Blood samples (2 mL each) were collected at 2, 4, 6, 8, 18, 24, 36, and 44 h postinjection to assess the bone marrow absorbed dose. Organ doses were calculated using the OLINDA/EXM software based on scintigraphic images of the 18 patients who received 177Lu-PSMA-617.
Results: The blood clearance of 177Lu-PSMA-617 radiopharmaceutical was determined to be bi-exponential. The mean absorbed doses for the parotid glands, kidneys, bone marrow, and liver were found to be 1.18 ± 0.27, 1.05 ± 0.3, 0.07 ± 0.05, and 0.31 ± 0.2 Gy/GBq, respectively. The radiation dose to the bone marrow was significantly lower than that to the kidneys and parotid glands. No dose limitations were necessary for kidneys and bone marrow in any of the patients.
Conclusions: Our dosimetry results indicate that 177Lu-PSMA-617 therapy is safe in terms of radiation toxicity.
期刊介绍：
JOURNAL OF MEDICAL PHYSICS is the official journal of Association of Medical Physicists of India (AMPI). The association has been bringing out a quarterly publication since 1976. Till the end of 1993, it was known as Medical Physics Bulletin, which then became Journal of Medical Physics. The main objective of the Journal is to serve as a vehicle of communication to highlight all aspects of the practice of medical radiation physics. The areas covered include all aspects of the application of radiation physics to biological sciences, radiotherapy, radiodiagnosis, nuclear medicine, dosimetry and radiation protection. Papers / manuscripts dealing with the aspects of physics related to cancer therapy / radiobiology also fall within the scope of the journal.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
